Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
about
Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for interventionBiologic and clinical significance of androgen receptor variants in castration resistant prostate cancerNovel pharmacological approaches for the treatment of acne vulgarisMinireview: Pathophysiological roles of the TR4 nuclear receptor: lessons learned from mice lacking TR4Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cellsTherapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerAndrogen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals.Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.Opportunities and challenges in combination gene cancer therapy.Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals.ELF5-Mediated AR Activation Regulates Prostate Cancer Progression.Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Targeting the androgen receptor in prostate cancer.Androgen receptor splice variants in the era of enzalutamide and abiraterone.Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.Leading causes of castration-resistant prostate cancer.Overview on the complexity of androgen receptor-targeted therapy for prostate cancerProstate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Biological and pharmacological evaluation of dimethoxycurcumin: A metabolically stable curcumin analogue with a promising therapeutic potential.Targeting metastasis.TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures.Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-β1/Smad/MMP9 signalsAnti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.Androgen receptor variation affects prostate cancer progression and drug resistance.Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway.Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate CancerOvercoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor.Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade.Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression.Danshen improves survival of patients with advanced lung cancer and targeting the relationship between macrophages and lung cancer cells.Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide.
P2860
Q21129293-6844CCF0-3467-4838-8536-94B4E26795C6Q26858922-7D1F329B-912F-4AA4-8FB7-72501474CE01Q28241186-777B8646-B81A-4172-BB00-000BFB546265Q33701419-3614BE26-D34F-4667-9325-A815849B9FFFQ34389853-C8A94400-7BF7-4F7E-925E-A6506C116B8AQ34416771-EE90AEE8-9BA0-4A0D-B9E8-F3BED6C333F5Q36298863-B487E7F4-37BF-4D4A-BED9-D44A23EEB812Q36413827-263D87D2-46A9-43EA-8A13-751C22E2D7CFQ36946815-5F3073F0-CE30-4508-A2F0-BD27341F2544Q37118663-69DDAF8D-14DF-4908-A06A-92CF649E1319Q37376793-FA464995-5152-4048-9652-DAA2FF9982AEQ37437329-C15C9ED0-2905-4560-8CB0-6EB2D6862523Q37687068-1DFC7E92-CB83-4233-A27B-AA6A9C7B17CEQ37695373-1E0B7D81-3ECC-4AB9-B1E7-7FD40C62D088Q37706057-58CD5FFD-CE3D-4CD0-8BEA-017C6DD824ADQ38203779-B62DE581-7A70-4776-8078-6B8BD352CA4BQ38217060-BF44F1FC-D66D-420B-849B-3EB2D8535CB9Q38232413-447044EB-C338-4C4F-8F88-128ED2C6341DQ38272331-55DE8E7C-A133-4107-A876-3102BF13FAD6Q38341864-4C7D1E4B-C1F6-4ADC-851F-4BBBDBF4BAA5Q38364166-B3198C00-EB70-4E03-9507-1DD5A72247AEQ38643148-FF148385-57C4-468A-B25C-F35EB23EA425Q38743727-8DA44B9D-B3A8-46C0-BB5A-AD74D99EB3D0Q38780353-6A3E3C5F-5D50-428F-849D-7AB19333D294Q38786658-0ED335EE-6FE5-48A2-BAF1-ED3866D8AE3FQ38839046-E95217A6-BA67-4936-B257-9B3114A78610Q38875469-FFE5C911-196D-4F16-AB23-BBFA9E6CD66CQ38879139-437BD47C-717D-4397-B6D2-07BDC58460D1Q38893994-B53C0A32-2835-46E7-A77A-BED5703AECE3Q38964798-23282746-A128-42E4-BECA-E0F7A09231DCQ38977288-3C7210F6-2427-479D-84D0-320CD33D8DDDQ38981044-3F8AD436-3299-4094-AC31-1956F5B3D311Q39152842-F8075AE7-5D95-44D8-8796-3A8AE888E0E5Q39438805-81DADF28-25BA-405A-9C11-9D56EB44F2D3Q41112355-5ADB2046-D845-4A99-B260-D1A9643EC8FCQ41167484-7CB0381B-3EFD-45FC-8413-B6A0818BB2B2Q41347965-44E50012-B1B5-4A25-9455-9B0DC50D85AAQ41891349-AA223B22-9934-4509-9A13-4A9187B7C1F0Q47148987-605AF1C7-0E59-42D0-BB35-74E235352A47Q47438384-582ACCF1-F0C0-4E92-B4E5-6B2E3CE0B476
P2860
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-androgen receptor ASC-J9 ...... tion and STAT3-CCL2 signaling.
@en
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100
@nl
type
label
Anti-androgen receptor ASC-J9 ...... tion and STAT3-CCL2 signaling.
@en
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100
@nl
prefLabel
Anti-androgen receptor ASC-J9 ...... tion and STAT3-CCL2 signaling.
@en
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100
@nl
P2093
P2860
P356
P1476
Anti-androgen receptor ASC-J9 ...... tion and STAT3-CCL2 signaling.
@en
P2093
P2860
P356
10.1038/CDDIS.2013.270
P577
2013-08-08T00:00:00Z